Top 5 dvm360 videos of 2024: #5

As 2024 draws to a close, dvm360 is counting down our Top 5 videos of 2024. The ranking is based on measurable interest and engagement from our digital viewers. These 5 videos feature thought leaders from throughout the veterinary care industry, who discuss a variety of topics.

The #5 video on the Top 5 countdown features Mara Tugel, DVM, veterinary technical marketing-companion animal therapeutics for Elanco. In an interview with dvm360, Tugel gives viewers an overview of the product and how it can help improve the lives of canines suffering from these dermatology diseases, and the benefits it has for clients.

The following is a partial video report:

Mara Tugel, DVM: Zenrelia, or the drug name illunocitinib, is a Janus kinase or JAK inhibitor that was recently approved by the FDA to control pruritus in dogs with allergic dermatitis and control atopic dermatitis in dogs that are over 12 months of age. So it can be used for both short term acute cases of allergies like flea hypersensitivity or contact allergies or even flare ups in a longer term case, and it could also be used for long term treatment, as in chronic cases of atopy. What's really great about Zenrelia is that the dose has been optimized to allow for once daily dosing from the start, and this has some really clear advantages for both veterinarians and pet owners.

First of all, it's just simpler. So communicating once daily dosing from the beginning to a pet parent is easier than talking about having to do a dosing change partway through treatment.

View the video here.